Nucleix

Israel
Reẖovot, Central District, Israel, 7670203

Company profile

Nucleix company profile

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Business identity

Contact email
[email protected]
Phone number
+97289161616
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2008-01-01, Year

Headquarters

Postal code
7670203
Country code
IL
Continent
Asia

Capital profile

Funding and company signals

Funding rounds
5
Total equity funding
$80M
Last funding
Series Unknown / $22M / 2022-01-05
Last equity funding
Series Unknown / $22M
Investors
14
Lead investors
3
Founders
3
Articles
31

Founders and investors

Founders

Adam WasserstromDanny FrumkinElon Ganor

Lead investors

Horizon 2020RA Capital ManagementSands Capital Ventures

Investors

BlackRockLilly Asia VenturesOrbiMedRA Capital ManagementSands Capital Ventures